Merck Submits Januvia/Metformin NDA Aiming To Launch First Fixed-Dose DPP-4 Inhibitor
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis, meanwhile, is positioning its investigational DPP-4 inhibitor Galvus as an add-on to metformin.